Two Sigma Advisers
KAPA

Two Sigma Advisers’s Kairos Pharma KAPA Stock Holding History

Two Sigma Advisers’s Portfolio KAPA Stock Details KAPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,142
Closed -$10.8K – 2267
2025
Q4 		$10.8K Buy
+15,142
New +$14.2K ﹤0.01% 2325

Other funds holding KAPA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
SFG
SevenBridge Financial Group Harrisburg, Pennsylvania $640M AUM 27.29% 1-Year Est. Return
ACA
Aptus Capital Advisors Fairhope, Alabama $12.7B AUM 17.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Two Sigma Advisers's KAPA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Kairos Pharma (KAPA) in Q1 2026, closing a stake of 15,142 shares — an estimated $10.8K sold.

Two Sigma Advisers first reported a position in KAPA in Q4 2025 and held it in 1 quarter. The position peaked at $10.8K in Q4 2025. 11 funds tracked by Wall St. Rank hold KAPA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Kairos Pharma position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 15,142 Kairos Pharma shares in Q1 2026, an estimated $10.8K.
  • Two Sigma Advisers first reported a position in Kairos Pharma in Q4 2025 and held it in 1 quarter.
  • Two Sigma Advisers's Kairos Pharma position peaked at $10.8K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held Kairos Pharma as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.